FibroGen Rebrands to Kyntra Bio, Changes Ticker to KYNB, Signaling Strategic Pivot
Summary
FibroGen, Inc. has rebranded to Kyntra Bio, effective January 7, 2026, with its common stock trading under the new Nasdaq symbol "KYNB" from January 8, 2026, reflecting a strategic pivot towards oncology and rare disease assets.
Key Events
-
Company Name Change
FibroGen, Inc. officially changed its name to Kyntra Bio, Inc., effective January 7, 2026.
-
Ticker Symbol Change
The company's common stock will begin trading under the new Nasdaq symbol "KYNB" at market open on January 8, 2026.
-
Strategic Rebranding
The rebranding reflects a sharpened strategic focus on developing novel therapies in oncology and rare diseases, following a transformational year for the company.
-
Bylaws Amendment
The company's bylaws were amended to reflect the new corporate name, Kyntra Bio, Inc.
Analysis
The rebranding of FibroGen to Kyntra Bio, accompanied by a new ticker symbol, signifies a major strategic transformation for the company. This move follows a "transformational year" that included the sale of FibroGen China, debt repayment, and an extended cash runway. The new identity underscores a sharpened focus on developing novel therapies in oncology and rare diseases, particularly highlighting assets like FG-3246 (ADC) and roxadustat for myelodysplastic syndromes. For investors, this signals a clear strategic direction and a renewed commitment to specific therapeutic areas, potentially impacting future growth and valuation.
At the time of this filing, FGEN was trading at $9.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $4.85 to $21.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.